Literature DB >> 18245082

Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Latha Devi1, Vijayendran Raghavendran, Badanavalu M Prabhu, Narayan G Avadhani, Hindupur K Anandatheerthavarada.   

Abstract

Alpha-synuclein, a protein implicated in the pathogenesis of Parkinson disease (PD), is thought to affect mitochondrial functions, although the mechanisms of its action remain unclear. In this study we show that the N-terminal 32 amino acids of human alpha-synuclein contain cryptic mitochondrial targeting signal, which is important for mitochondrial targeting of alpha-synuclein. Mitochondrial imported alpha-synuclein is predominantly associated with the inner membrane. Accumulation of wild-type alpha-synuclein in the mitochondria of human dopaminergic neurons caused reduced mitochondrial complex I activity and increased production of reactive oxygen species. However, these defects occurred at an early time point in dopaminergic neurons expressing familial alpha-synuclein with A53T mutation as compared with wild-type alpha-synuclein. Importantly, alpha-synuclein that lacks mitochondrial targeting signal failed to target to the mitochondria and showed no detectable effect on complex I function. The PD relevance of these results was investigated using mitochondria of substantia nigra, striatum, and cerebellum of postmortem late-onset PD and normal human brains. Results showed the constitutive presence of approximately 14-kDa alpha-synuclein in the mitochondria of all three brain regions of normal subjects. Mitochondria of PD-vulnerable substantia nigra and striatum but not cerebellum from PD subjects showed significant accumulation of alpha-synuclein and decreased complex I activity. Analysis of mitochondria from PD brain and alpha-synuclein expressing dopaminergic neuronal cultures using blue native gel electrophoresis and immunocapture technique showed the association of alpha-synuclein with complex I. These results provide evidence that mitochondrial accumulated alpha-synuclein may interact with complex I and interfere with its functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245082      PMCID: PMC2431021          DOI: 10.1074/jbc.M710012200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Authors:  Lee J Martin; Yan Pan; Ann C Price; Wanda Sterling; Neal G Copeland; Nancy A Jenkins; Donald L Price; Michael K Lee
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

Review 2.  The biochemistry of Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Human mitochondrial complex I assembly is mediated by NDUFAF1.

Authors:  Rutger O Vogel; Rolf J R J Janssen; Cristina Ugalde; Melissa Grovenstein; Richard J Huijbens; Henk-Jan Visch; Lambert P van den Heuvel; Peter H Willems; Massimo Zeviani; Jan A M Smeitink; Leo G J Nijtmans
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

5.  Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants.

Authors:  Tobias S Ulmer; Ad Bax
Journal:  J Biol Chem       Date:  2005-09-15       Impact factor: 5.157

6.  Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.

Authors:  Darren J Moore; Li Zhang; Juan Troncoso; Michael K Lee; Nobutaka Hattori; Yoshikuni Mizuno; Ted M Dawson; Valina L Dawson
Journal:  Hum Mol Genet       Date:  2004-11-03       Impact factor: 6.150

7.  Lewy bodies.

Authors:  Clifford W Shults
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

8.  Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein.

Authors:  Christopher E Ellis; Eric J Murphy; Drake C Mitchell; Mikhail Y Golovko; Fernando Scaglia; Gwendolyn C Barceló-Coblijn; Robert L Nussbaum
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

9.  Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.

Authors:  Wanli W Smith; Haibing Jiang; Zhong Pei; Yuji Tanaka; Hokuto Morita; Akira Sawa; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2005-10-20       Impact factor: 6.150

10.  Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism.

Authors:  Laura Silvestri; Viviana Caputo; Emanuele Bellacchio; Luigia Atorino; Bruno Dallapiccola; Enza Maria Valente; Giorgio Casari
Journal:  Hum Mol Genet       Date:  2005-10-05       Impact factor: 6.150

View more
  367 in total

Review 1.  The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease.

Authors:  Victor S Van Laar; Sarah B Berman
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

2.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

3.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

Review 4.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

5.  Mitochondrial viability in mouse and human postmortem brain.

Authors:  Keri A Barksdale; Emma Perez-Costas; Johanna C Gandy; Miguel Melendez-Ferro; Rosalinda C Roberts; Gautam N Bijur
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

6.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 7.  Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.

Authors:  Andrew B Knott; Ella Bossy-Wetzel
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

10.  Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Authors:  Adam L Orr; Florentine U Rutaganira; Daniel de Roulet; Eric J Huang; Nicholas T Hertz; Kevan M Shokat; Ken Nakamura
Journal:  Neurochem Int       Date:  2017-04-20       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.